OGNHIGH SIGNALFINANCIAL10-K

Organon experienced a dramatic collapse in net income while maintaining relatively stable revenue performance, signaling significant margin compression or extraordinary charges.

The company's profitability deteriorated substantially year-over-year despite only modest gross profit decline, suggesting either major one-time charges, increased operating expenses, or structural margin pressures. The concurrent reduction in dividends paid reflects management's response to the earnings decline, while the increase in stockholders' equity provides some balance sheet cushioning during this challenging period.

Comparing 2026-02-24 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

Organon's financial performance shows a stark disconnect between top-line stability and bottom-line results, with net income falling dramatically while gross profit declined only modestly. Operating cash flow decreased meaningfully but remained positive at $700M, though dividend payments were substantially reduced in response to the earnings pressure. The balance sheet showed some strengthening with higher stockholders' equity and reduced current liabilities, providing financial flexibility despite the profitability challenges.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-78.4%
$864.0M$187.0M

Net income declined 78.4% — review whether driven by operations, interest costs, or non-recurring items.

Dividends Paid
Cash Flow
-70.4%
$297.0M$88.0M

Dividends cut 70.4% — significant signal of cash flow stress or capital reallocation priorities.

Stockholders Equity
Balance Sheet
+59.3%
$472.0M$752.0M

Equity base grew 59.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Operating Cash Flow
Cash Flow
-25.5%
$939.0M$700.0M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Cash & Equivalents
Balance Sheet
-15%
$675.0M$574.0M

Cash decreased 15% — monitor burn rate and upcoming capital needs.

Current Liabilities
Balance Sheet
-12.1%
$2.7B$2.4B

Current liabilities reduced — improved short-term financial position and working capital health.

Gross Profit
P&L
-10.8%
$3.7B$3.3B

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-28
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 41 Item 7A.
Form 10-K Summary 115 Signatures 116 The following notations in this Annual Report on Form 10-K (this 2025 Form 10-K ) have the meanings as set forth below: Indicates, in this 2025 Form 10-K, brand names of products, which are not available in the United States.
( Organon, the Company, we, our, or us ) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day.
With a portfolio of over 70 products across women s health and general medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 countries and territories.
We operate six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom ( UK ).
+7 more — sign up free →
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 38 Item 7A.
Form 10-K Summary 101 Signatures 102 The following notations in this Annual Report on Form 10-K (this 2024 Form 10-K ) have the meanings as set forth below: Indicates, in this 2024 Form 10-K, brand names of products, which are not available in the United States.
( Organon, the Company, we, our, or us ) is a global healthcare company with a primary focus on improving the health of women throughout their lives.
We develop and deliver innovative health solutions through a portfolio of prescription therapies and medical devices within women s health, biosimilars and established brands.
We have a portfolio of more than 70 medicines and products across a range of therapeutic areas.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →